Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03069365 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
A Phase 3 study of Hepatitis C Virus (HCV), sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
- 20
- Study locations
NCT03069365 is a Phase 3 study of Hepatitis C Virus (HCV) that has completed, run by AbbVie. The registered enrollment target is 101 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT03069365, a Phase 3 study of Hepatitis C Virus (HCV), has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a Phase 3b, open-label, non-randomized, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection without liver cirrhosis or with compensated liver cirrhosis and with chronic renal impairment in participants who were either HCV treatment-naïve (TN) or prior treatment-experienced (TE) with interferon (IFN) or pegylated interferon (PegIFN) with or without ribavirin (RBV), or sofosbuvir (SOF) plus RBV with or without pegIFN.
Conditions Studied
Interventions
- DRUG Glecaprevir/pibrentasvir
Study Locations (20)
California
- Scripps Clinic /ID# 159116 - La Jolla
- Huntington Medical Foundation /ID# 160653 - Pasadena
New York
- North Shore University Hospital /ID# 159108 - New Hyde Park
- Columbia Univ Medical Center /ID# 159112 - New York
Pennsylvania
- University of Pennsylvania /ID# 159117 - Philadelphia
- Thomas Jefferson University /ID# 159754 - Philadelphia
British Columbia
- Vancouver ID Research and Care /ID# 160598 - Vancouver
- GIRI Gastrointestinal Research Institute /ID# 160599 - Vancouver
Other
- Med Hochschule Hanover /ID# 160827 - Hanover
- Univ Johannes Gutenberg /ID# 160828 - Mainz
Florida
- Tampa General Medical Group /ID# 159115 - Tampa
Louisiana
- Northwest Louisiana Nephrology /ID# 160652 - Shreveport
Massachusetts
- Massachusetts General Hospital /ID# 159114 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-03-28 |
| Est. Completion | 2018-06-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03069365
The ClinicalTrials.gov registry entry for NCT03069365 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C Virus (HCV) appearing as the primary indexed condition, and to 1 intervention - of which Glecaprevir/pibrentasvir is the first listed.
NCT03069365 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03069365 about?
NCT03069365 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment". This was a Phase 3b, open-label, non-randomized, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection without liver cirrhosis or with compensated liver cirrhosis and with chronic...
What is the current status of trial NCT03069365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2017-03-28. Estimated completion is 2018-06-05.
What conditions does trial NCT03069365 study?
This clinical trial studies the following conditions: Hepatitis C Virus (HCV).
What interventions are being tested in trial NCT03069365?
The interventions under investigation include: Glecaprevir/pibrentasvir (DRUG).
Who is sponsoring clinical trial NCT03069365?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03069365 being conducted?
This trial has 20 study locations across California, Florida, Louisiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C Virus (HCV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.